移至主內容

Update on BIMERVAX® immunogenicity amplitude. Insights on humoral response against XBB.1.5 from an extension study

COVID-19

Borralleras C, Castrodeza J, Arrazola P, Cámara-Hijón C, Eiros JM, Fernández M, et al.  

 

The World Health Organization (WHO), in May 2023, and the European Medicines Agency (EMA), in June 2023, published their recommendations on the composition of COVID-19 vaccines for the 2023-24 season. These recommendations, published after the acceptance of the manuscript, oblige the authors to produce a brief update and reinforce the BIMERVAX® vaccine positioning based on new evidence from the pivotal clinical trial (HIPRA-HH-2 extension, NCT05142553).